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Demonstrating a slowing in the rate of cognitive decline is a common outcome
measure in clinical trials in Alzheimer’s disease (AD). Selection of cognitive endpoints
typically includes modeling candidate outcome measures in the many, richly phenotyped
observational cohort studies available. An important part of choosing cognitive
endpoints is a consideration of improvements in performance due to repeated cognitive
testing (termed “practice effects”). As primary and secondary AD prevention trials are
comprised predominantly of cognitively unimpaired participants, practice effects may
be substantial and may have considerable impact on detecting cognitive change.
The extent to which practice effects in AD prevention trials are similar to those from
observational studies and how these potential differences impact trials is unknown.
In the current study, we analyzed data from the recently completed DIAN-TU-001
clinical trial (TU) and the associated DIAN-Observational (OBS) study. Results indicated
that asymptomatic mutation carriers in the TU exhibited persistent practice effects on
several key outcomes spanning the entire trial duration. Critically, these practice related
improvements were larger on certain tests in the TU relative to matched participants from
the OBS study. Our results suggest that the magnitude of practice effects may not be
captured by modeling potential endpoints in observational studies where assessments
are typically less frequent and drug expectancy effects are absent. Using alternate
instrument forms (represented in our study by computerized tasks) may partly mitigate
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practice effects in clinical trials but incorporating practice effects as outcomes may
also be viable. Thus, investigators must carefully consider practice effects (either by
minimizing them or modeling them directly) when designing cognitive endpoint AD
prevention trials by utilizing trial data with similar assessment frequencies.
Keywords: practice effects, Alzheimer’s disease, clinical trials, learning, assessment frequency, alternative forms

equivalent (Gross et al., 2012), and yet still limit PEs due to
familiarity. Computerized cognitive assessments, depending on
the test paradigms, can protect against form-related PEs by
randomly selecting stimuli for each test administration, creating
an essentially endless number of alternate forms. But of course,
this requires additional equipment and study management that
can be costly and may not suit all trial protocols. Importantly,
none of these approaches are entirely successful at eliminating
practice effects (Beglinger et al., 2005; Falleti et al., 2006). Given
the difficulties with eliminating PEs in cognitive studies, some
studies have turned away from efforts at avoiding PEs opting
instead to determine if incorporating PEs as outcomes themselves
may reveal meaningful information about cognitive status. For
example, several studies have shown that the attenuation of PEs
in clinically healthy older adults can predict important outcomes
such as biomarker status or risk of progression to symptomatic
AD (Duff et al., 2011; Hassenstab et al., 2015; Machulda et al.,
2017; Oltra-Cucarella et al., 2018; Samaroo et al., 2020). PEs may
therefore serve as a subtle marker of early disease even if average
cognitive trajectories are relatively flat. It is critical, therefore,
to have a comprehensive understanding of factors that produce
or exaggerate practice effects and to develop statistical tools to
appropriately model them. Ultimately, the magnitude of PEs may
serve as an alternative or supplementary endpoint for trials.
Similar to clinical trials, observational studies of AD provide
systematic and longitudinal assessment of clinical, cognitive and
pathological progression of the disease, albeit in the absence of
a specific intervention. Although PEs have been relatively well
studied in community-based observational studies of sporadic
AD, to date, we are unaware of any systematic evaluation
of PEs in the context of a clinical trial. One might expect
that PEs would be attenuated in clinical trials if the study
protocol includes a comprehensive screening assessment, which
may provide exposure to the testing materials (Goldberg et al.,
2015). Alternatively, in some cases, trial participants might be
recruited from ongoing observational studies and hence are
already familiar with the process of cognitive testing and may
have exposure to the same test materials. Another important
difference from observational studies is the role of participant
expectations in clinical trials. Trial participants may exhibit
enhanced PEs due to a type of placebo effect, wherein motivation
and engagement may be higher in the trial compared to
observational studies where expectations and motivations for
participation may be different. As many trials rely on data from
observational studies to select appropriate cognitive measures as
endpoints and conduct power analyzes to determine the requisite
sample sizes needed to detect a hypothetical treatment effect, it is
critical to test the assumption that participants in observational
studies will perform similarly to those engaged in clinical trial

INTRODUCTION
Phase 3 secondary prevention clinical trials in Alzheimer’s disease
aim to demonstrate the efficacy of drug or other interventions in
preserving or improving cognitive function in at-risk individuals.
Such trials typically use the slowing of the rate of cognitive decline
between a treatment arm and a placebo group as their primary
efficacy endpoint (Sperling et al., 2014; Bateman et al., 2017;
Cummings et al., 2020). Comprehensive neuropsychological test
batteries are administered at regular intervals (e.g., every 6–
12 months) to best characterize cognitive change across the
course of the trial and to monitor for adverse events such
as unexpected drops in performance. However, these repeated
administrations may have unanticipated consequences for trial
outcomes. Specifically, it is well-known that healthy adults
typically improve in performance (termed “practice effects”
or “PEs”) with repeated cognitive testing (Calamia et al.,
2012). These PEs can be attributed to several factors including
increased familiarity with task procedures, development of
testing strategies, or memorization of specific stimuli. These
gains are not limited to short time intervals and can persist
for as long as 7 years (Salthouse et al., 2004) after just one
exposure, a longer time span than a typical AD prevention
trial. It is also important to consider that in symptomatic AD
populations, where active neurodegenerative processes drive
worsening cognitive performance, practice effects do not always
translate to better performance from visit to visit. Rather, the
competing forces of disease and PEs can manifest as attenuations
of decline such that PEs may be observable as flat or simply less
negative slopes.
For these reasons, potential PEs must be taken into
consideration when planning a clinical trial. The two primary
analytical models used in AD trials either analyze change from
baseline to final test (e.g., mixed models for repeated measures
or MMRM) or conceptualize change as linear from baseline
to end of study (random intercept and slope models). When
PEs are present but unaccounted for in statistical models,
the magnitude of decline over the course of the trial can
be drastically underestimated (Hassenstab et al., 2015; Jacobs
et al., 2017) reducing the power to detect a treatment effect.
Therefore, it may be desirable to minimize the influence of
PEs in a clinical trial. One way to do so would be to include
multiple “screening” sessions (Goldberg et al., 2015) which
give participants experience with the cognitive battery prior
to the initiation of treatment, as PEs tend to be largest after
the first or second retest (Collie et al., 2003; Bartels et al.,
2010). Other methods for minimizing PEs include the use of
alternate forms, although this presents the additional challenge
of verifying that the different forms are truly psychometrically
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not considered. A small number of NMCs had clinical evidence
for impairment (3 in the TU and 7 in OBS), these participants
were removed prior to analysis due to small sample size, leaving
a total of 374 participants available for analysis.

research. If these two populations differ in terms of PEs or
overall cognitive trajectories, pre-specified cognitive endpoints
selected based on observational study data may not be suitable
for a clinical trial and sample sizes may be underestimated,
among other concerns.
To address these issues, we present analyzes from the recently
completed DIAN-TU 001 (TU) clinical trial (Mills et al., 2013)
and the associated DIAN Observational study (OBS, Bateman
et al., 2012). The DIAN-TU is a phase 2/3, double blind, placebo
controlled study of disease modifying therapies in autosomal
dominant AD (ADAD), a rare form of AD due to specific genetic
mutations that has similar pathological and clinical presentations,
other than in age at onset, as sporadic AD (Bateman et al.,
2011). These genetic mutations cause AD with virtually 100%
penetrance and onset of clinical symptoms begin at a predictable
and typically much younger age than sporadic AD (Ryman
et al., 2014). The expected number of years to symptom onset
(EYO) can be calculated based on the participant’s age and the
historical average age-at-symptomatic onset of gene-carriers with
the same mutation or from the same family. The predictability
of expected symptom onset as well as pathological similarities
to the more common sporadic form of AD, makes ADAD a
critical population in which to understand and build a model of
cognitive, clinical, and pathological disease progression (McDade
et al., 2018). To maintain participant blinding to their mutation
status, ADAD mutation carriers (MCs) and non-carriers (NMCs)
were enrolled in the trial, with all NMCs being assigned to
placebo in a double blinded manner. The DIAN Observational
study was launched in 2008 to provide natural history data on
the progression of clinical, cognitive, and pathological changes
in this population. Several participants who enrolled in the
OBS study later enrolled in the TU study. We utilized the
data from these two studies to answer the following questions:
(1) Do PEs in ADAD vary as a function of mutation status
or clinical status? (2) Do alternate forms that vary the stimuli
across repeated administration (computerized battery vs. pen and
paper) moderate the size of PEs? and (3) Do cognitive trajectories
in clinical trials differ from those in observational only studies?

Clinical/Cognitive Evaluation
Participants in both the TU and OBS studies underwent
comprehensive clinical and cognitive evaluations. Presence and
severity of dementia symptoms was ascertained using the Clinical
Dementia Rating (CDR) scale (Morris, 1993). A global rating
of 0 on the CDR reflects no dementia, while scores of 0.5,
1, 2, and 3 reflect very mild, mild, moderate, and severe
dementia, respectively. The Mini-Mental State Exam (Folstein
et al., 1975) (MMSE) was also given as a measure of general
cognitive function.
The cognitive batteries were largely similar across the two
studies. Neuropsychological tests that were given in common
across the two cohorts have been described elsewhere (Storandt
et al., 2014) and include Wechsler Memory Scale-Revised Logical
Memory Immediate and Delayed Recall (Wechsler, 1987) and
Digit Span, Trail making Parts A and B (Armitage, 1945),
Category Fluency for Animals and Vegetables (Goodglass and
Kaplan, 1983), and Digit Symbol Substitution from the Wechsler
Adult Intelligence Scale-Revised (Wechsler, 1981). In the TU,
participants were also administered the Cogstate computerized
battery which included Identification, Detection, One-Back, One
Card Learning, and the International Shopping List test. These
measures have been described extensively elsewhere (Hammers
et al., 2011; Lim et al., 2012). In the TU, most of these tests
were administered every 6 months except for category fluency
and the MMSE which were measured annually. All tests utilized
the same versions at each testing occasion with the exception of
the Cogstate tests which produced randomly generated stimuli
at each occasion. Assessment frequency in the OBS study ranged
from every 1–3 years depending on clinical status and when the
participant entered the study. The OBS study has enrolled over
575 participants to date, but for the purpose of these analyzes, we
selected participants that matched the enrollment criterion for
the TU. We included as many participants as possible who met
the following criteria: baseline global CDR score of 1 or less and
estimated years to EYO range from –15 to +10 years (Salloway
et al., 2021; See Table 1 for full demographics). For the purposes
of these analyzes, participants who were initially enrolled in the
OBS study and then transitioned to the TU (41% of the TU CDR
0 carriers, 32% of the TU CDR > 0 carriers and 33% of the TU
non-carriers started in the OBS study) were included in the TU
cohort but were excluded from analyzes in the OBS cohort.
R

MATERIALS AND METHODS
A total of 384 participants were included in our analyzes. Onehundred ninety-three participants from the TU cohort and 191
from the OBS cohort. Both studies recruited a population of
ADAD mutation carriers and non-carriers to determine the
natural history (OBS) and to implement safe, efficient, and
effective clinical trials that have the highest likelihood of success
in advancing overall treatment (TU). Although the TU study
was not powered to determine cognitive effects at the higher
treatment doses that were ultimately used (5% power to detect a
30% slowing in the rate of cognitive decline), we have previously
shown the absence of a treatment effect on cognitive outcomes
in the TU (Salloway et al., 2021). Thus, given the relatively small
group differences between treatment and placebo arms, for the
present analyzes, all participants were combined and treatment
arm [e.g., drug (solanezumab/gantenerumab) vs. placebo] was
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Statistical Analysis
Our analyzes proceeded in several steps. We first compared
cognitive trajectories in the TU battery between NMCs, CDR
0 MCs and CDR > 0 MCs. We constructed linear mixed
effects (LME) models for each cognitive test and predicted
cognition from baseline EYO, time-in-study (hereafter referred
to as “time”), group and the group by time interaction. A random
intercept and random slope of time was also included in
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TABLE 1 | Demographic characteristics of the clinical trial (TU) and observational (OBS) study cohorts.
DIAN-TU
NMC

MC CDR 0

DIAN Obs
MC CDR > 0

NMC

MC CDR 0

MC CDR > 0

46

85

59

115

35

34

Age

42.0 (9.2)

40.9 (8.5)

49.2 (10.1)

41.3 (8.9)

38.7 (9.5)

46.0 (8.3)

EYO

–4.5 (6.3)

–5.8 (6.3)

2.7 (4.8)

–6.1 (6.8)

–8.3 (6.0)

1.2 (3.9)

Sex (% female)

20 (43%)

45 (53%)

28 (47%)

70 (61%)

25 (71%)

22 (65%)

Education

15.5 (3.2)

15.6 (3.2)

14.1 (2.6)

14.9 (2.8)

14.3 (2.7)

13.2 (3.2)

Number of assessments

7.3 (3.6)

9.5 (2.2)

8.1 (2.5)

2.2 (1.3)

2.7 (1.1)

3.3 (1.2)

Length of follow-up

3.1 (1.8)

4.2 (1.1)

3.6 (1.3)

2.5 (2.5)

3.6 (1.9)

2.9 (1.6)

N

Results are reported as mean (SD) where appropriate.

Identification and One back, Digit Symbol Substitution and
Trail Making Part A). In contrast, cognitive trajectories for
the MC CDR 0 group were relatively flat with a few notable
exceptions. There was significant decline on Category Fluency
for Animals, the ISLT and the Identification test, suggesting that
measures of semantic fluency, episodic memory and attention are
sensitive to preclinical cognitive decline. Interestingly, the Logical
Memory immediate and delayed recall tests showed significant
improvement over time in this population as did Cogstate One
Card Learning, a test of visual learning ability. NMCs did not
decline on any measure, which was expected in a relatively young
and cognitively healthy cohort. Showing the classic pattern of
practice effects, NMCs exhibited significant improvement over
time compared to a zero slope on several measures including
Logical Memory Immediate and Delayed Recall, Digit Symbol
Substitution, Digit Span Backward and One Card Learning.
In order to determine disease effects on learning and decline,
we next compared slopes between the NMCs and the MC CDR
0 group (shown in Figure 2) to determine if differences in rate
of change distinguished the groups. Slopes (reflecting change
per year in z-score units) were significantly different between
these two groups on the following measures: One Card Learning
(Difference = 0.10, p = 0.01, CI = 0.02:0.18), Logical Memory
Immediate (Difference = 0.16, p = 0.009, CI = 0.04:0.27), Logical
Memory Delayed (Difference = 0.14, p = 0.007, CI = 0.04:0.24),
Digit Span Forward (Difference = 0.11, p = 0.04, CI = 0.006:0.21),
Digit Span Backward (Difference = 0.13, p = 0.02, CI = 0.03:0.23)
and the ISLT (Difference = 0.19, p < 0.001, CI = 0.08:0.30).
These results indicate that while both MCs and NMCs exhibited
PEs (see Figure 1) on the Logical Memory and One Card
Learning tests, practice-related gains were significantly larger in
the NMCs. Moreover, NMCs improved over time on the Digit
Span Backward test whereas the MCs showed no significant
change. Finally, the NMCs did not show improvement or decline
on ISLT whereas the MCs significantly declined.

all models with an unstructured covariance matrix. Followup contrasts were constructed to compare slopes on each test
between the NMCs and the CDR 0 MCs, and between the CDR 0
MCs and the CDR > 0 MCs. For ease of comparison across tests,
all outcomes were z-scored to the baseline mean and standard
deviation of the CDR 0 non-carriers so that a score of “0”
represents the score of a relatively cognitively normal participant.
Scores were oriented such that a positive slope indicates an
improvement over time and a negative slope indicates decline.
A second set of LMEs were constructed to compare
performance in the TU vs. the OBS study. Specifically, we
analyzed performance on each cognitive test as a function of
time, group (NMC, CDR 0 MC, and CDR > 0 MCs) and
cohort (TU vs. OBS), and included all of the two and three-way
interactions while also controlling for baseline EYO. All models
were fit in the R statistical computing software (version 4.0.5,
R Core Team, 2021) using the lme4 package (version 1.1.27.1,
Bates et al., 2015). P-values were obtained using the lmerTest
(version 3.1.3, Kuznetsova et al., 2017) package. To ensure that
no influential, outlying data points were unduly biasing our
results, we used the infleunce.ME package (Nieuwenhuis et al.,
2012) to iteratively remove a single participant from each model
and re-run the statistical analysis. We checked for a change
in statistical significance in key model parameters (specifically,
the group by time or group by cohort by time interactions)
when a given participant was removed. Across all the analyses
we conducted, none of those parameters changed significance
suggesting no single person was exerting undue influence on
these results. Finally, although a relatively large set of statistical
comparisons were conducted in order to fully describe practice
effects across a range of cognitive tests, no corrections for
multiple comparisons were made.

RESULTS
Analysis 1: Clinical Trial Only

Analysis 2: Observational Versus Clinical
Trial

Slopes over time for each cognitive test and each group are
illustrated in Figure 1. Intercepts and slope scores for each test
can also be found in Supplementary Table 1. Not surprisingly,
the MC CDR > 0 group evinced significant decline on all
cognitive measures with some of the largest effects occurring
on tests of perceptual speed and attention (Cogstate Detection,
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Intercepts and slopes for the eligible participants in the OBS
study are provided in Supplementary Table 2, and slopes for
each test and group are plotted in Figure 3, showing timedependent changes. First, similar to the TU, the MC CDR > 0
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FIGURE 1 | Slope estimates and 95% confidence intervals for each test and clinical group in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU).
Slopes can be considered significant if the CI does not encompass zero. All tests were scaled such that a negative slope indicates decline. Slopes are in z-score
units change per year. (A) Plots non-carriers (N = 46), (B) plots Clinical Dementia Rating (CDR) 0 mutation carriers (N = 85), and (C) plots CDR > 0 mutation carriers
(N = 59). Due to dramatic performance differences across groups, the X-axis scale is not identical across the panels. ONB, one-back; OCL, one card learning; Det,
detection; Idn, identification; ISLT, international shopping list; Veg, category fluency for vegetables; animals, category fluency for animals; DigFor and DigBack, digit
span forward and backward; LM, logical memory; MMSE, Mini Mental State Exam.

FIGURE 2 | Differences in slopes (and 95% CIs) for each test between non-carriers and CDR 0 mutation carriers in the clinical trial (TU). A positive slope difference
indicates a larger or more positive slope (improvement) in the non-carriers compared to mutation carriers. Mean difference and 95% confidence intervals are pasted
along the left side.

group in the observational study declined significantly on all
measures. Second, the MC CDR 0 group again showed relatively
flat cognitive trajectories with the notable exception of the Digit
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Symbol Substitution test which significantly declined by 0.12
z-score units per year. Most importantly, there was no hint of
practice related improvements in the MC CDR 0s, with lack
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FIGURE 3 | Slope estimates and 95% confidence intervals for each test and clinical group in the DIAN-Observational (DIAN-Obs) study. Slopes are expressed as
z-score units change per year and can be considered significant if the CI does not encompass zero. All tests were scaled such that a negative slope indicates
decline. (A) Plots non-carriers (N = 115), (B) plots CDR 0 mutation carriers (N = 35), and (C) plots CDR > 0 mutation carriers (N = 34). Due to dramatic performance
differences across groups, the X-axis scale is not identical across the panels.

questions regarding practice related improvements
observational studies and clinical trials in AD populations.

of evidence of positive slope estimates, on any of the cognitive
measures. Finally, the NMC group significantly improved on
the Logical Memory Immediate and Delayed Recall tests but
the slopes for the other measures were relatively flat and not
significantly different from zero.
Direct comparisons between the symptomatic MCs in the OBS
and TU cohorts (Figure 4), revealed no significant differences in
slopes between the cohorts on any measure with the exception of
Logical Memory Immediate Recall (Difference = 0.18, p = 0.03,
CI = 0.02:0.34), in which participants in the TU showed slightly
less decline than in OBS. Interestingly, a number of differences
emerged when comparing the asymptomatic MCs across TU and
OBS (Figure 5). Specifically, on the Digit Symbol Substitution
test (Difference = 0.14, p = 0.02, CI = 0.02:0.25), Logical Memory
Immediate (Difference = 0.15, p = 0.03, CI = 0.02:0.28) and
Delayed recall (Difference = 0.15, p = 0.007, CI = 0.04:0.26)
slopes were markedly less negative in the TU as compared to the
OBS study. Finally, in the comparison of NMCs (Figure 6), the
OBS participants improved less on Logical Memory Immediate
(Difference = 0.19, p = 0.003, CI = 0.07:0.31) and Delayed recall
(Difference = 0.20, p < 0.001, CI = 0.10:0.30) compared to the
TU participants.

Question 1: Does Mutation Status or
Clinical Status Moderate Practice Effects
in the Dominantly Inherited Alzheimer
Network Trials Unit?
Clinical status was an important predictor of PEs in the DIANTU. Specifically, individuals who were CDR > 0 at entry
significantly declined on all cognitive measures and therefore
did not show practice-related gains. This is not to say that PEs
were not present in this group, only that any gains associated
with practice were overshadowed by the decline attributable
to AD pathology. More importantly, mutation status in the
CDR 0 groups also predicted magnitude of change in the TU.
MC CDR 0s declined significantly over time on measures of
attention, episodic memory, and semantic fluency whereas NMCs
showed no change in these domains. Interestingly, differences in
performance between MC CDR 0s and NMCs also emerged on
the ISLT (list recall, MCs declined more than NMCs), Logical
Memory (narrative recall, MCs improved less than NMCs),
Digit Span (working memory, MCs improved less than NMCs),
and One Card Learning (visual learning, MCs improved less
than NMCs). Together these findings suggest that differences in
the magnitude of practice related improvements in domains of
memory and learning might serve as a sensitive and supplemental
indicator of preclinical AD.

DISCUSSION
In this study, we compared performance on a comprehensive
cognitive battery in two cohorts to answer several important
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FIGURE 4 | Differences in slopes (and 95% CIs) for each test between CDR > 0 mutation carriers in TU vs. the Obs study. A positive slope difference indicates a
larger or more positive slope (improvement) in the TU compared to the Obs study. Some tests, such as Logical Memory, had more improvement or practice effects in
the TU vs. Obs. Mean differences and 95% CIs presented along the right side of the graph.

FIGURE 5 | Differences in slopes (and 95% CIs) for each test between CDR 0 mutation carriers in TU vs. the Obs study. A positive slope difference indicates a larger
or more positive slope (improvement) in the TU compared to the Obs study. Some tests, such as Logical Memory and Digit Symbol, had more improvement or
practice effects in the TU vs. Obs. Mean differences and 95% CIs presented along the left side of the graph.

Our hypothesis was largely supported. Most of the
computerized tests were resistant to practice effects in the
NMCs or sensitive to decline in the MCs (e.g., ISLT and
Identification tests). Practice related gains were apparent on the
One Card Learning test and due to the nature of the randomized
stimuli, it is assumed that participants are developing or learning
some strategy besides rote memorization to improve over time.
One possibility is that this test might be particularly amenable to
visual strategies such as the method of loci (Gross et al., 2014).
As the cards are shown one at a time, participants may over time
learn to organize the items in a meaningful fashion (e.g., into
poker hands or by suit) which might aid recall.

Question 2: Do Alternative Forms
Influence Practice Effects?
We expected a priori that computerized measures from the
Cogstate battery might show less practice effects due to the nature
of randomized stimuli which generates essentially unlimited
alternate forms. For example, many of these tasks use playing
cards as stimuli presented in a newly randomized order at
each administration. Such a design reduces the possibility of
memorizing specific items which can be a contributor to PEs.
This contrasts with Logical Memory in the DIAN studies,
for example, which presents the same narrative each time
the test is taken.
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FIGURE 6 | Differences in slopes (and 95% CIs) for each test between non-mutation carriers in TU vs. the Obs study. A positive slope difference indicates a larger or
more positive slope (improvement) in the TU compared to the Obs study. Some tests, such as Logical Memory had more improvement or practice effects in the TU
vs. Obs. Mean differences and 95% CIs presented along the right side of the graph.

measures (Calamia et al., 2012). Thus, frequency of assessment
needs to be carefully considered during trial design.
Another important possibility is an enhanced placebo effect
in the DIAN-TU. Specifically, TU participants were randomized
to treatment vs. placebo at a ratio of 3:1. Thus, there may
have been a greater expectation of being on active drug which
may have then impacted cognitive performance. Regardless
of the underlying mechanisms, these differences in practice
related gains are particularly noteworthy as the Logical Memory
and Digit Symbol tests feature heavily in multiple cognitive
composite endpoints (Sperling et al., 2014; Bateman et al., 2017).
Investigators should keep in mind potential differences between
observational and trial cohorts when planning their studies and
conducting power analyzes.
Using alternate instrument forms has been shown in some
studies to be a viable strategy to reduce PEs. For example, a
meta-analysis of test/retest effects found substantial reductions
in performance gains when alternate forms were used for verbal
list learning measures (Calamia et al., 2012). This finding is
similar to the results shown here, in which the computerized
tests were largely resistant to practice-related gains. The one
exception we found was One Card Learning, a visual learning
test that uses randomly generated sequences of cards such that
there are essentially hundreds of alternate forms. This task
produced the largest PEs in asymptomatic MCs enrolled in the
DIAN-TU clinical trial. We could not, however, determine if
this was due solely to clinical trial participation, as this measure
was not collected with sufficient samples in the OBS study
for comparison. In a recent study, the developers of the One
Card Learning test made a shorter and less difficult version of
the test (as evidenced by less floor effects in symptomatic AD
participants) that demonstrated no PEs in young cognitively

Question 3: Are Practice Effects Similar
Across Clinical Trials and Observational
Studies?
One of the most important questions addressed in this study was
whether cognitive trajectories were similar across a clinical trial
cohort and an observational study. For participants who were
CDR > 0 at baseline, the answer was clearly “yes”. Regardless
of the cohort, MC CDR > 0s declined significantly over time
and the magnitude of change did not differ significantly between
the TU and OBS with the sole exception of Logical Memory
Immediate Recall. This may reflect disease progression such
that symptomatic MCs have declined to the extent that any
practice related gains were outweighed by the task demands.
An interesting but complex question for future studies is to
determine the point at which PEs are effectively overwhelmed by
disease related declines.
For the MC CDR 0s, however, a few critical differences
did emerge. Specifically, OBS participants declined at a faster
rate than the TU participants on the Digit Symbol Substitution
test and improved less on the Logical Memory Immediate
and Delayed Recall tests. One obvious possible explanation for
these differences is the assessment frequency across the two
studies (every 6 months in the TU, ∼ every 2 years in OBS).
This explanation is likely for the Logical Memory tests, where
participants will hear the same story at each testing occasion
which reinforces encoding and aids in recall. It is less clear why
Digit Symbol Substitution would show such enhanced practice
effects in the TU when other measures of speed and executive
function did not (e.g., the Trail Making tests). Studies of retest
have shown performance gains on Digit Symbol Substitution, but
this test typically demonstrates less gains than episodic memory
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this is a study of ADAD, a very rare form of AD, the sample
sizes included here could be considered small. Moreover, it is
unclear whether differences in practice related gains will translate
to the more common sporadic form of the disease. Second,
some participants in these studies may become aware of their
mutation status and this might alter their cognitive outcomes
(Aschenbrenner et al., 2020). It is unknown whether the number
of participants who did and did not learn their status were similar
across the two studies. Third, we did not have data from the
Cogstate testing battery in the DIAN-OBS study which precluded
a comparison of PEs between the trial and observational study on
these measures. Finally, we conducted many statistical tests due
to the large cognitive battery that was administered and although
many effects could have been predicted a priori this could be
seen as an additional limitation.
Nevertheless, these results highlight three important points.
(1) Practice effects were highly evident in the DIAN-TU-001
clinical trial in asymptomatic mutation carriers and non-carriers.
(2) Alternate forms may have attenuated practice effects, but
not for all measures. (3) The magnitudes of practice effects
were larger in the DIAN-TU-001 clinical trial than seen in
a well-matched sample from the DIAN Observational study,
suggesting that more frequent assessments and placebo effects
in clinical trials may drive increases in practice effects. Clinical
trials that utilize a cognitive endpoint should carefully consider
the potential for practice effects and select statistical modeling
strategies that can incorporate them directly.

normal participants across very short retest intervals (White et al.,
2021). The authors argue that the increased difficulty and length
of the longer version of the task may lead to participants forming
strategies that in turn lead to more PEs.
Although our results indicate that rates of change on key
cognitive outcomes may be underestimated in clinical trials
due to the presence of these practice effects, it is important to
highlight situations in which these practice effects might limit
the ability to detect treatment effects. Specifically, in clinical
trials that include a placebo arm in which participants undergo
identical clinical and cognitive assessments as participants on
active treatment, the negative impact of practice effects may be
minimal, to the extent that practice effects manifest similarly
in placebo vs. treated patients. However, this also assumes
that the influence of improved cognition due to treatment is
additive, rather than interactive, with improved cognition due
to practice effects, which may not be the case. Moreover, the
primary cognitive outcome is often a composite score formed of
multiple tests. If some tests exhibit practice effects while others
do not, as is the case in the present study, decline on a global
composite score may be very small, limiting the power to detect
any differences among groups.
It is unclear if attempts to avoid or reduce practice effects
are futile. Completely avoiding practice effects does seem an
impossible task. One of the most fundamental aspects of human
behavior is adaptation, or learning. As we and others have
previously shown, in the context of a cognitive assessment this
learning is not just limited to familiarity with test materials
but also to process factors like test strategies, effort, demand
characteristics, and expectancy effects, among others (Beglinger
et al., 2005; Hassenstab et al., 2015; Machulda et al., 2017).
Instead of avoiding PEs, trials that enroll cognitively normal
or mildly affected participants might consider designs and
statistical models that anticipate and account for the influence
of PEs. Such protocols might include extended baseline designs
that allow cluster assessments prior to dosing in so-called
“run-in” designs (Frost et al., 2008). Less emphasis might be
placed on spreading assessments out at regular time intervals
(e.g., one assessment every 6 months) in favor of clustering
assessments at key read-out times and averaging across the
clusters, which might not only minimize the effects of practice
but also reduce individual variability in scores (Valdes et al.,
2016). An alternative strategy is to incorporate PEs as outcomes
themselves. Several recent studies have deliberately measured
learning effects in cognitively normal older adults at risk for
AD (Hassenstab et al., 2015; Baker et al., 2020; Lim et al., 2020;
Samaroo et al., 2020). Effect sizes differentiating participants with
biomarker-confirmed preclinical AD from those with normal
biomarker levels are extraordinarily large for these paradigms,
suggesting that PEs may be a highly sensitive indicator of
disease progression.
There are many strengths to this study including use of a
comprehensive cognitive battery on very well-characterized
clinical cohorts, designed comparability between an
observational study and clinical trial, enrolling the same
population for both studies, and frequent assessments over many
years. However, some limitations need to be noted. First, because
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